Clinical cancer immunotherapy: Current progress and prospects

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chenglong, Yang, Mengxuan, Zhang, Daizhou, Chen, Ming, Zhu, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592930/
https://www.ncbi.nlm.nih.gov/pubmed/36304470
http://dx.doi.org/10.3389/fimmu.2022.961805
_version_ 1784815041866891264
author Liu, Chenglong
Yang, Mengxuan
Zhang, Daizhou
Chen, Ming
Zhu, Di
author_facet Liu, Chenglong
Yang, Mengxuan
Zhang, Daizhou
Chen, Ming
Zhu, Di
author_sort Liu, Chenglong
collection PubMed
description Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.
format Online
Article
Text
id pubmed-9592930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95929302022-10-26 Clinical cancer immunotherapy: Current progress and prospects Liu, Chenglong Yang, Mengxuan Zhang, Daizhou Chen, Ming Zhu, Di Front Immunol Immunology Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9592930/ /pubmed/36304470 http://dx.doi.org/10.3389/fimmu.2022.961805 Text en Copyright © 2022 Liu, Yang, Zhang, Chen and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Chenglong
Yang, Mengxuan
Zhang, Daizhou
Chen, Ming
Zhu, Di
Clinical cancer immunotherapy: Current progress and prospects
title Clinical cancer immunotherapy: Current progress and prospects
title_full Clinical cancer immunotherapy: Current progress and prospects
title_fullStr Clinical cancer immunotherapy: Current progress and prospects
title_full_unstemmed Clinical cancer immunotherapy: Current progress and prospects
title_short Clinical cancer immunotherapy: Current progress and prospects
title_sort clinical cancer immunotherapy: current progress and prospects
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592930/
https://www.ncbi.nlm.nih.gov/pubmed/36304470
http://dx.doi.org/10.3389/fimmu.2022.961805
work_keys_str_mv AT liuchenglong clinicalcancerimmunotherapycurrentprogressandprospects
AT yangmengxuan clinicalcancerimmunotherapycurrentprogressandprospects
AT zhangdaizhou clinicalcancerimmunotherapycurrentprogressandprospects
AT chenming clinicalcancerimmunotherapycurrentprogressandprospects
AT zhudi clinicalcancerimmunotherapycurrentprogressandprospects

Ejemplares similares